Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease

Figure 5 Senicapoc prevents steatosis in the CDAHFD Model. In animals fed CDAHFD for a week, co-treatment with Senicapoc, A: Decreased NAS (0-8 scale); B: Decreased steatosis (0-3 scale); C: Decreased the lipid vacuole area measured by planimetry in H&E-stained sections; and D: Treatment with Senicapoc reduced hepatic lipid peroxidation (4-HNE) observed in the CDAHFD + vehicle cohort. ^aP < 0.05 vs vehicle.